Pharmaxis (Pharmaxis) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 06, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pharmaxis's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Pharmaxis's Margin of Safety % (DCF Earnings Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmaxis's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaxis's Margin of Safety % (DCF Earnings Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmaxis's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Pharmaxis's Margin of Safety % (DCF Earnings Based) falls into.

Pharmaxis Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaxis (Pharmaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines

From GuruFocus

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

By PRNewswire PRNewswire • 08-05-2021

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

By PRNewswire PRNewswire • 08-04-2021

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

By PRNewswire PRNewswire • 11-09-2021

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

By PRNewswire PRNewswire • 10-05-2021

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis

By Business Wire Business Wire • 11-02-2020

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

By PRNewswire PRNewswire • 08-31-2021